Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 19 (3) , 271-276
Abstract
No abstract availableKeywords
Funding Information
- University of İstinye, Turkey (2018-003/015)
This publication has 35 references indexed in Scilit:
- Changes of placental syndecan-1 expression in preeclampsia and HELLP syndromeVirchows Archiv, 2013
- Molecular functions of syndecan-1 in diseaseMatrix Biology, 2012
- Shedding of Syndecan–1 From Human Hepatocytes Alters Very Low Density Lipoprotein ClearanceHepatology, 2011
- Syndecan expressions in the human amnion and chorionic plateEuropean Journal of Histochemistry, 2010
- Pregnancy Outcomes during an Era of Aggressive Management for Intrahepatic Cholestasis of PregnancyAmerican Journal of Perinatology, 2008
- Heparan sulphate proteoglycans fine-tune mammalian physiologyNature, 2007
- Adenovirus‐mediated hepatic syndecan‐1 overexpression induces hepatocyte proliferation and hyperlipidaemia in miceLiver International, 2007
- Preeclampsia with Abnormal Liver Function Tests Is Associated with Cholestasis in a Subgroup of CasesHypertension in Pregnancy, 2004
- Obstetric cholestasis, outcome with active management: a series of 70 casesBJOG: An International Journal of Obstetrics & Gynaecology, 2002
- Intrahepatic cholestasis of pregnancy: Perinatal outcome associated with expectant managementAmerican Journal of Obstetrics and Gynecology, 1996